Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Wullich

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
Metabolomics : Official Journal of the Metabolomic Society|June 26, 2025
Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohortsSimon Heckscher, Nicolas A Ihlo, Jan Schueler, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Cancer Immunology Research|April 17, 2019
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer SubtypesCarolin Pfannstiel, Pamela L Strissel, Katherine B Chiappinelli, et al.
Clinical Genitourinary Cancer|May 29, 2017
Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center CohortMalte W Vetterlein, Christian P Meyer, Sami-Ramzi Leyh-Bannurah, et al.
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Human Pathology|August 20, 2018
High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinomaIris Polifka, Abbas Agaimy, Edwin Herrmann, et al.
The Journal of Urology|December 17, 2009
Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological reviewEdwin Herrmann, Lutz Trojan, Frank Becker, et al.
International Journal of Cancer|April 25, 2025
Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?Christoph Schubart, Lars Tögel, Maria Giulia Carta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinomaNiklas Klümper, Danijel Sikic, Jonas Saal, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
Metabolomics : Official Journal of the Metabolomic Society|June 26, 2025
Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohortsSimon Heckscher, Nicolas A Ihlo, Jan Schueler, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Cancer Immunology Research|April 17, 2019
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer SubtypesCarolin Pfannstiel, Pamela L Strissel, Katherine B Chiappinelli, et al.
Clinical Genitourinary Cancer|May 29, 2017
Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center CohortMalte W Vetterlein, Christian P Meyer, Sami-Ramzi Leyh-Bannurah, et al.
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Human Pathology|August 20, 2018
High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinomaIris Polifka, Abbas Agaimy, Edwin Herrmann, et al.
The Journal of Urology|December 17, 2009
Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological reviewEdwin Herrmann, Lutz Trojan, Frank Becker, et al.
International Journal of Cancer|April 25, 2025
Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?Christoph Schubart, Lars Tögel, Maria Giulia Carta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinomaNiklas Klümper, Danijel Sikic, Jonas Saal, et al.
Pageof 26